Alert: Did You Lose Money on Your Cronos Investment? Contact Johnson Fistel Regarding Investigation

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON) for violations of federal securities laws.

On November 9, 2021, Cronos filed a Form 8-K with the SEC stating that "On November 8, 2021, Cronos Group Inc. (the "Company"), on the recommendation of the Audit Committee of the Company's Board of Directors, and after consultation with KPMG LLP, the Company's independent registered public accounting firm, determined that it will be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021, previously filed on Form 10-Q on August 6, 2021. The Company's financial statements for this period should therefore no longer be relied upon."

Following this news, the companies share price dropped 16% during mid-day trading hours of November 9, 2021.

If you have information that could assist in this investigation, including past employees and others, or if you are a Cronos shareholder and are interested in learning more about the investigation, please contact Jim Baker ( jimb@johnsonfistel.com ) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [ Click here to join this action ]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com . Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[ Click here to join thi s action ]


News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Cannabis buds on a wooden surface with Australian banknotes nearby.

Australia's Cannabis Import Quota Slashed Amid Surging Local Production

Australia’s Office of Drug Control (ODC) said that the country’s 2025 cannabis import quota has officially been reduced by the International Narcotics Control Board (INCB) from 101 tonnes to 88 tonnes, Business of Cannabis reported on Tuesday (October 28).Demand over projections and idle permits... Keep Reading...
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
Field of cannabis plants under bright sunlight.

Cannabis Market Update: H1 2025 in Review

The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...

Latest Press Releases

Related News